Neumora director receives 80,000 stock options
Neumora Therapeutics director David Piacquad received a grant of stock options for 80,000 shares of Common Stock at an exercise price of $1.86 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Neumora Therapeutics director David Piacquad received a grant of stock options for 80,000 shares of Common Stock at an exercise price of $1.86 per share. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date, and expire on May 26, 2036.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Piacquad David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 80,000 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Key Figures
Option grant size: 80,000 options
Exercise price: $1.86 per share
Underlying shares: 80,000 shares
+3 more
6 metrics
Option grant size
80,000 options
Stock Option (Right to Buy) awarded to director
Exercise price
$1.86 per share
Conversion or exercise price of options
Underlying shares
80,000 shares
Common Stock underlying the options
Total options after grant
80,000 options
Total derivative securities following transaction
Expiration date
May 26, 2036
Option expiration date
Vesting reference date
May 27, 2026
One-year anniversary used in vesting schedule
Key Terms
Stock Option (Right to Buy), Common Stock, vest, Annual Meeting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vest financial
"100% of the shares subject to the option vest on the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Annual Meeting financial
"immediately prior to the next Annual Meeting following May 27, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Neumora Therapeutics (NMRA) report for David Piacquad?
Neumora Therapeutics reported that director David Piacquad received a grant of 80,000 stock options. These options give him the right to buy Neumora Common Stock at a fixed exercise price of $1.86 per share if they vest and are exercised.
What are the key terms of David Piacquad’s 80,000 Neumora (NMRA) stock options?
The grant covers 80,000 options to purchase Neumora Common Stock at an exercise price of $1.86 per share. The options expire on May 26, 2036, providing a long-term window for potential exercise if vesting conditions are satisfied.
When do David Piacquad’s Neumora (NMRA) stock options vest?
All 80,000 options vest 100% on the earlier of two dates. Vesting occurs on the one-year anniversary of May 27, 2026 or immediately before the next Neumora Annual Meeting following May 27, 2026, whichever happens first under the award terms.
Does the Form 4 for Neumora (NMRA) show a stock purchase or sale by David Piacquad?
The Form 4 shows an option grant, not an open‑market stock purchase or sale. It reports a compensation-related acquisition of 80,000 stock options with an exercise price of $1.86 per share and no shares bought or sold in the market.
How many Neumora (NMRA) derivative securities does David Piacquad hold after this transaction?
Following the transaction, David Piacquad holds 80,000 stock options as reported. These options are derivative securities tied to Neumora Common Stock, giving him the right to purchase 80,000 underlying shares at $1.86 per share if exercised after vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates